Bank of America Securities Remains Bullish on Ultragenyx Pharmaceutical (RARE)

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the best biotech stocks with high potential. On October 3, Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and set a price target of $79.00.

Ultragenyx (RARE) Falls 26% as New Treatment Fails to Get FDA Green Light

Ultragenyx Pharmaceutical Inc. reported $166 million in total revenue for fiscal Q2 2025, with Crysvita® revenue of $120 million and Dojolvi® revenue of $23 million.

The company also reaffirmed its 2025 revenue guidance and now expects total revenue in the $640 million to $670 million range

Ultragenyx Pharmaceutical Inc. develops, acquires, and commercializes novel products to treat genetic diseases. Its product portfolio includes Crysvita, Mepsevii, Dojolvi, and Evkeeza.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

This article is originally published at Insider Monkey.